Major Obstacle to Adoptive Cell Transfer Therapy Could be Overcome - European Medical Journal

Major Obstacle to Adoptive Cell Transfer Therapy Could be Overcome

2 Mins

A NOVEL cancer treatment could be a step closer to being made available for patients following the results of a study that showed that altering a powerful immune-signalling chemical and its receptor on immune cells eased the side effects of the therapy.

Boosting IL-2 Levels
Researchers from Stanford University, California, USA, were able to develop a method of boosting IL-2 levels after adoptive cell transfer therapy that does not have the side effects caused by intravenous IL-2 administrations. In adoptive cell transfer, during which killer T cells are modified and returned to the patient’s circulatory system where they can destroy tumours efficiently and selectively, the modified T cells require frequent boosts of IL-2 to survive. Using intravenous IL-2 administrations has lead to severe side effects, such as pulmonary oedema.

Engineering an altered version of one of IL-2’s constituent subunits prevented a receptor containing this subunit from binding to IL-2; additionally, the team generated a slightly tweaked IL-2 molecule that couldn’t bind to its normal receptor. Snapping the modified receptors onto mice T cells, it was shown that these T cells responded to modified IL-2 the same as would occur naturally. However, T cells that were unaltered did not respond to the modified IL-2 at all.

Mouse Model
In a mouse model, the team compared the use of adoptive cell therapy followed by frequent IL-2 infusions with the therapy preceded by the new method. While adoptive cell therapy was effective both times, IL-2 infusions caused a number of nasty side effects. This compared to no side effects when the T cells were bioengineered and outfitted with the modified receptors.

Revolutionary New Approach
“Adoptive cell therapy is on the cusp of becoming a revolutionary new approach to cancer treatment,” explained Prof Christopher Garcia, Stanford University. “It’s undergoing explosive growth: it’s a multibillion-dollar biotechnology industry already, and it’s going to become as routine as bone marrow transplants are now. But all of the approaches in development today need IL-2, so new and better ways of delivering IL-2 are a critical unmet need. Our approach is also applicable to other important immune substances and cell types.”

James Coker, Reporter

For the source and further information about the study, click here.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now